TY - JOUR
T1 - Rare clinical manifestations in systemic lupus erythematosus
T2 - a review on frequency and clinical presentation
AU - Tani, Chiara
AU - Elefante, Elena
AU - Arnaud, Laurent
AU - Barreira, Sofia C
AU - Buliņa, Inita
AU - Cavagna, Lorenzo
AU - Costedoat-Chalumeau, Nathalie
AU - Doria, Andrea
AU - Fonseca, João Eurico
AU - Franceschini, Franco
AU - Fredi, Micaela
AU - Iaccarino, Luca
AU - Limper, Maarten
AU - Majnik, Judit
AU - Nagy, Gyorgy
AU - Pamfil, Cristina
AU - Rednic, Simona
AU - Reynolds, John A
AU - Tektonidou, Maria G
AU - Troldborg, Anne
AU - Zanframundo, Giovanni
AU - Mosca, Marta
N1 - Funding Information:
Funding and disclaimer: page S99. Competing interests: L. Arnaud has acted as a consultant for Alexion, Amgen, Astra-Zeneca, Abbvie, Biogen, BMS, Boehringer-Ingelheim, Cemka, GSK, Grifols, Janssen-Cilag, Kezar, LFB, Lilly, Medac, Novartis, Oséus, Pfizer, Roche-Chugai, Semeia, UCB. I. Bulina has received honoraria from Abbvie, Boehringer-Ingelheim, Janssen and Pfizer. N. Costedoat-Chalumeau has received grants from UCB for a clinical research study. The other authors have declared no competing interests.
Publisher Copyright:
© Copyright Clinical and Experimental Rheumatology 2022.
PY - 2022/5
Y1 - 2022/5
N2 - OBJECTIVES: The purpose of this study was to review the frequency and clinical presentation of the rarest clinical manifestations of systemic lupus erythematosus (SLE).METHODS: A list of 6 rare SLE manifestations were defined: gastrointestinal, liver, pulmonary, cardiac, ocular and neurological manifestations. Each topic was assigned to a pair of authors to perform a literature search and article review.RESULTS: In total, 149 articles were included in the literature review: 37 for gastrointestinal manifestations, 6 for liver manifestations, 27 for pulmonary manifestations, 50 for cardiac manifestations, 16 for ocular manifestations, 13 for neurological manifestations. Gastrointestinal disorders included several clinical presentations with variable frequency (from 0.5% to 10.7% of the cases); liver involvement included lupus-related hepatitis (9.3%) and autoimmune hepatitis (2.3%). The rarest pulmonary manifestations identified were shrinking lung syndrome, described in 1.5% of patients, while interstitial lung disease and lupus pneumonia were reported in 4% and 3% of patients respectively. Myocarditis and pulmonary hypertension were also rarely described in SLE patients although ranging from 0.4-16% and 1-14% respectively, depending on the methodology used for its identification. Ocular manifestations in SLE included some rare manifestations (reported in less than 5% of patients) and lupus retinopathy that is described in 1.2-28.8% of patients depending on methods of ascertainment. Aseptic meningitis and chorea were also confirmed as very rare manifestations being reported in less than 1% and in 0.3-2.4% of cases respectively.CONCLUSIONS: The results of this literature review provide the basis for a better understanding of some less-known manifestations of SLE and for stressing the need for a higher awareness in diagnostic and therapeutic protocols regarding these rare disease aspects.
AB - OBJECTIVES: The purpose of this study was to review the frequency and clinical presentation of the rarest clinical manifestations of systemic lupus erythematosus (SLE).METHODS: A list of 6 rare SLE manifestations were defined: gastrointestinal, liver, pulmonary, cardiac, ocular and neurological manifestations. Each topic was assigned to a pair of authors to perform a literature search and article review.RESULTS: In total, 149 articles were included in the literature review: 37 for gastrointestinal manifestations, 6 for liver manifestations, 27 for pulmonary manifestations, 50 for cardiac manifestations, 16 for ocular manifestations, 13 for neurological manifestations. Gastrointestinal disorders included several clinical presentations with variable frequency (from 0.5% to 10.7% of the cases); liver involvement included lupus-related hepatitis (9.3%) and autoimmune hepatitis (2.3%). The rarest pulmonary manifestations identified were shrinking lung syndrome, described in 1.5% of patients, while interstitial lung disease and lupus pneumonia were reported in 4% and 3% of patients respectively. Myocarditis and pulmonary hypertension were also rarely described in SLE patients although ranging from 0.4-16% and 1-14% respectively, depending on the methodology used for its identification. Ocular manifestations in SLE included some rare manifestations (reported in less than 5% of patients) and lupus retinopathy that is described in 1.2-28.8% of patients depending on methods of ascertainment. Aseptic meningitis and chorea were also confirmed as very rare manifestations being reported in less than 1% and in 0.3-2.4% of cases respectively.CONCLUSIONS: The results of this literature review provide the basis for a better understanding of some less-known manifestations of SLE and for stressing the need for a higher awareness in diagnostic and therapeutic protocols regarding these rare disease aspects.
KW - Hepatitis, Autoimmune
KW - Humans
KW - Hypertension, Pulmonary
KW - Lung Diseases
KW - Lupus Erythematosus, Systemic/complications
UR - http://www.scopus.com/inward/record.url?scp=85130765664&partnerID=8YFLogxK
U2 - 10.55563/clinexprheumatol/jrz47c
DO - 10.55563/clinexprheumatol/jrz47c
M3 - Review article
C2 - 35485422
SN - 0392-856X
VL - 40
SP - S93-S102
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
IS - 5 (Suppl.134)
ER -